

# Alex C Spyropoulos

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3916166/alex-c-spyropoulos-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 papers	12,404 citations	43 h-index	111 g-index
163 ext. papers	15,274 ext. citations	7.4 avg, IF	6.35 L-index

#	Paper	IF	Citations
150	Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis.. <i>Thrombosis Research</i> , <b>2022</b> , 209, 94-98	8.2	7
149	Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e025342	6	
148	The HEP-COVID Trial. <i>Heart International</i> , <b>2021</b> , 15, 62	0.3	
147	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.. <i>Lancet, The</i> , <b>2021</b> ,	40	34
146	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	1
145	Studying the coagulopathy of COVID-19. <i>Lancet, The</i> , <b>2021</b> ,	40	4
144	Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021579	6	1
143	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1612-1620	11.5	81
142	A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 159-167	5.1	2
141	Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2021</b> , 27, 10760296211053316	3.3	1
140	Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019459	6	13
139	Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 897-901	5.1	14
138	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1684-1695	7.5	5
137	Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19. <i>TH Open</i> , <b>2021</b> , 5, e211-e219	2.7	2
136	Sex-Based Differences in COVID-19 Outcomes. <i>Journal of Women's Health</i> , <b>2021</b> , 30, 492-501	3	8
135	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , <b>2021</b> , 235, 12-23	4.9	14
134	Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. <i>Blood</i> , <b>2021</b> , 137, 2838-2847	2.2	59

133	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12520	5.1	3
132	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 992-1007	7	6
131	External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 1032-1035	5.1	4
130	Vascular thromboembolic events following COVID-19 hospital discharge: Incidence and risk factors. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12547	5.1	1
129	Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 12-16	5.1	
128	Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 330-336	2.3	10
127	Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1043-1053	7	21
126	Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2021</b> , 42, 308-315	3.9	2
125	Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 296-300	5.1	13
124	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2772-2780	15.4	0
123	Medically Ill hospitalized Patients for COVID-19 THrombosis Extended Prophylaxis with rivaroxaban Therapy: Rationale and Design of the MICHELLE Trial. <i>American Heart Journal</i> , <b>2021</b> , 242, 115-122	4.9	10
122	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. <i>Blood</i> , <b>2020</b> , 135, 1788-1810	2.2	33
121	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1004-1024	7	147
120	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 1859-1865	15.4	367
119	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 3140-3147	15.1	23
118	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 924-936	7	5
117	Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 559-568	5.1	4
116	Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. <i>TH Open</i> , <b>2020</b> , 4, e59-e65	2.7	74

115	Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy. <i>Lancet Haematology, the</i> , <b>2020</b> , 7, e247-e258	14.6	10
114	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 515-524	7	11
113	External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model. <i>Oncologist</i> , <b>2020</b> , 25, e1083-e1090	5.7	11
112	Hospital-based use of thromboprophylaxis in patients with COVID-19. <i>Lancet, The</i> , <b>2020</b> , 395, e75	40	29
111	Emergence of institutional antithrombotic protocols for coronavirus 2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 510-517	5.1	37
110	Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry. <i>Blood</i> , <b>2020</b> , 136, 33-34	2.2	2
109	Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant-Reply. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 333-334	11.5	
108	Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. <i>TH Open</i> , <b>2020</b> , 4, e344-e350	2.7	
107	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , <b>2020</b> , 76, 470-485	2.1	18
106	Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 316-320	5.1	5
105	Heparin Bridging Therapy for Patients on Chronic Oral Anticoagulants in Periprocedural Settings. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2020</b> , 46, 26-31	5.3	0
104	Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017316	6	5
103	Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study. <i>TH Open</i> , <b>2020</b> , 4, e255-e262	2.7	0
102	The underrecognized prothrombotic vascular disease of COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 942-943	5.1	2
101	Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. <i>Blood Advances</i> , <b>2020</b> , 4, 3520-3527	7.8	6
100	Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2020</b> , 26, 1076029620925910	3.3	1
99	Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2958-2967	15.4	69
98	The management of venous thromboembolism in hospitalized patients with COVID-19. <i>Blood Advances</i> , <b>2020</b> , 4, 4028	7.8	11

97	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1597-1628	7	73
96	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2950-2973	15.1	1682
95	New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
94	Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. <i>Thrombosis Research</i> , <b>2019</b> , 182, 159-166	8.2	29
93	Quality metrics of warfarin initiation in hospitalized older adults. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 459-465	5.1	
92	Assessment of warfarin algorithms for hospitalized adults: searching for a safe dosing strategy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 570-579	5.1	1
91	Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3256-3262	4	4
90	Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619850897	3.3	14
89	Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1966-1972	15.4	29
88	Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. <i>JAMA Internal Medicine</i> , <b>2019</b> , 179, 1469-1478	11.5	156
87	External validation of the COMPASS-Cancer Associated Thrombosis Study: A predictive score to identify patients with solid tumors on treatment who are at risk for venous thromboembolism.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18005-e18005	2.2	2
86	Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. <i>American Heart Journal</i> , <b>2019</b> , 212, 113-119	4.9	45
85	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2019</b> , 184, 58-61	8.2	13
84	Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2019</b> , 25, 1076029619886022	3.3	32
83	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2018</b> , 24, 575-582	3.3	14
82	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1118-1127	59.2	143
81	Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis. <i>JMIR MHealth and UHealth</i> , <b>2018</b> , 6, e11090	5.5	3
80	Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis. <i>Hospital Practice (1995)</i> , <b>2018</b> , 46, 5-15	2.2	7

79	Direct oral anticoagulants in the treatment of pulmonary embolism. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 131-140	2.5	9
78	Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2280	59.2	0
77	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 813-822	5.3	5
76	Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Circulation</i> , <b>2018</b> , 138, 1402-1411	16.7	14
75	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. <i>Oncologist</i> , <b>2017</b> , 22, 1222-1231	5.7	99
74	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2017</b> , 23, 532-541	3.3	7
73	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , <b>2017</b> , 1, e56-e65	2.7	62
72	The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 2415-2424	7	45
71	New paradigms in venous thromboprophylaxis of medically ill patients. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1662-1670	7	34
70	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <i>American Journal of Medicine</i> , <b>2016</b> , 129, S54-S63	2.4	9
69	External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 530-6	7	28
68	Cost-of-illness model for venous thromboembolism. <i>Thrombosis Research</i> , <b>2016</b> , 145, 130-2	8.2	7
67	Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 116, 544-53	7	20
66	European Union-28: An annualised cost-of-illness model for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 800-8	7	45
65	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 1240-8	7	52
64	The BRIDGE trial: What the hospitalist should know. <i>Journal of Hospital Medicine</i> , <b>2016</b> , 11, 652-7	2.7	2
63	Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 1001.e9-1001.e18	2.4	48
62	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , <b>2016</b> , 20, 115	10.8	35



61	Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1457-64	3	33
60	Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. <i>Hematology/Oncology Clinics of North America</i> , <b>2016</b> , 30, 1073-84	3.1	12
59	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <i>American Journal of Emergency Medicine</i> , <b>2016</b> , 34, 19-25	2.9	1
58	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 823-33	59.2	719
57	Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 113-24	2.9	10
56	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 625-32	7	158
55	All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 685-94	7	2
54	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated with Different Outcomes Among Patients with Venous Thromboembolism?. <i>Blood</i> , <b>2015</b> , 126, 1126-1126	2.2	1
53	External Validation of a Risk Assessment Model for Bleeding Risk in Medical Patients: Findings from the Improve Investigators in a Tertiary Health System. <i>Blood</i> , <b>2015</b> , 126, 748-748	2.2	
52	Treatment and long-term management of venous thromboembolism. <i>Clinics in Laboratory Medicine</i> , <b>2014</b> , 34, 519-36	2.1	2
51	Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. <i>Circulation</i> , <b>2014</b> , 130, 410-8	16.7	37
50	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , <b>2014</b> , 35, 3033-69, 3069a-3069k	9.5	1974
49	Venous thromboembolism risk in patients with inflammatory bowel disease: defining the benefits of pharmacologic prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1577	6.9	1
48	External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 692-9	7	54
47	Direct oral anticoagulants: new drugs and new concepts. <i>JACC: Cardiovascular Interventions</i> , <b>2014</b> , 7, 1333-51	5	67
46	Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (DOCKETT AF) Study. <i>Circulation</i> , <b>2014</b> , 129, 1273-8	16.7	188
45	External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e001152	6	83
44	Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. <i>Blood</i> , <b>2014</b> , 124, 1271-1271	2.2	

43	Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 36, 212-22	5.1	25
42	Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. <i>Thrombosis Research</i> , <b>2013</b> , 132, 520-6	8.2	37
41	Rivaroxaban for thromboprophylaxis in acutely ill medical patients. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 513-23	59.2	424
40	Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2013</b> , 15, 288-98	2.1	21
39	Venous thromboembolism management: where do novel anticoagulants fit?. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 783-90	2.5	6
38	Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2013</b> , 19, 504-12	3.3	8
37	Response. <i>Chest</i> , <b>2013</b> , 144, 1424-1426	5.3	2
36	Venous Thromboembolism Prevention in Hospitalized Medical and Surgical Patients <b>2013</b> , 741-745		
35	How I treat anticoagulated patients undergoing an elective procedure or surgery. <i>Blood</i> , <b>2012</b> , 120, 2954-62	4.62	265
34	Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 291-302	7	114
33	Pro: "Bridging anticoagulation is needed during warfarin interruption in patients who require elective surgery". <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 213-6	7	19
32	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1228-35	7	20
31	The use of weighted and scored risk assessment models for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1072-6	7	29
30	Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. <i>Circulation</i> , <b>2012</b> , 126, 1630-9	16.7	322
29	Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 1027-34	7	24
28	Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e326S-e350S	5.3	1175
27	Preventing VTE in Outpatients With Cancer. <i>Chest</i> , <b>2012</b> , 142, 265-266	5.3	3
26	Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 405-15	7	56



25	Predictive and associative models to identify hospitalized medical patients at risk for VTE. <i>Chest</i> , <b>2011</b> , 140, 706-714	5.3	278
24	The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 196-208	5.1	17
23	Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 407-16	5.1	84
22	Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. <i>Chest</i> , <b>2011</b> , 139, 69-79	5.3	253
21	The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. <i>Blood</i> , <b>2011</b> , 118, 542-542	2.2	2
20	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , <b>2011</b> , 118, 545-545	2.2	1
19	Bridging therapy and oral anticoagulation: current and future prospects. <i>Current Opinion in Hematology</i> , <b>2010</b> , 17, 444-9	3.3	24
18	Risk assessment of venous thromboembolism in hospitalized medical patients. <i>Current Opinion in Pulmonary Medicine</i> , <b>2010</b> , 16, 419-25	3	14
17	To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 29, 192-8	5.1	12
16	Rates of venous thromboembolism occurrence in medical patients among the insured population. <i>Thrombosis and Haemostasis</i> , <b>2009</b> , 102, 951-7	7	51
15	Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 28, 458-64	5.1	45
14	Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations. <i>Annals of Surgery</i> , <b>2009</b> , 250, 219-28	7.8	23
13	Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 883-9	3	73
12	The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 299S-339S	5.3	621
11	Epidemiology of venous thromboembolism in cardiorespiratory and infectious disease. <i>American Journal of Medicine</i> , <b>2008</b> , 121, 935-42	2.4	42
10	Investigational treatments of venous thromboembolism. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 431-40	5.9	30
9	Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. <i>Chest</i> , <b>2007</b> , 132, 936-45	5.3	377
8	Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 1109-22	2.5	41

7	Prevention of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2006</b> , 32, 755-66	5.3	25
6	Management of venous thromboembolism in the elderly. <i>Drugs and Aging</i> , <b>2006</b> , 23, 651-71	4.7	25
5	Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. <i>Chest</i> , <b>2005</b> , 128, 958-69	5.3	48
4	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 750-9	7	156
3	Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1149-59	3.5	63
2	Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. <i>Chest</i> , <b>2004</b> , 125, 1642-50	5.3	92
1	Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. <i>Chest</i> , <b>2002</b> , 122, 108-14	5.3	103